196 related articles for article (PubMed ID: 24954510)
1. Synuclein γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption.
Liang W; Miao S; Zhang B; He S; Shou C; Manivel P; Krishna R; Chen Y; Shi YE
Oncogene; 2015 Apr; 34(18):2398-405. PubMed ID: 24954510
[TBL] [Abstract][Full Text] [Related]
2. Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption.
Shao Y; Wang B; Shi D; Miao S; Manivel P; Krishna R; Chen Y; Eric Shi Y
Mol Oncol; 2014 Dec; 8(8):1521-31. PubMed ID: 24998446
[TBL] [Abstract][Full Text] [Related]
3. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma.
Bekki H; Kohashi K; Maekawa A; Yamada Y; Yamamoto H; Harimaya K; Hakozaki M; Nabeshima K; Iwamoto Y; Oda Y
BMC Cancer; 2015 Oct; 15():804. PubMed ID: 26502919
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
Calero R; Morchon E; Martinez-Argudo I; Serrano R
Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
7. The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG.
Lv C; Zeng HW; Wang JX; Yuan X; Zhang C; Fang T; Yang PM; Wu T; Zhou YD; Nagle DG; Zhang WD
Cell Death Dis; 2018 Feb; 9(2):165. PubMed ID: 29416003
[TBL] [Abstract][Full Text] [Related]
8. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
[TBL] [Abstract][Full Text] [Related]
9. The Herbal Combination Shu Gan Jie Yu Regulates the SNCG/ER-a/AKT-ERK Pathway in DMBA-Induced Breast Cancer and Breast Cancer Cell Lines Based on RNA-Seq and IPA Analysis.
Zhao Y; Zhao L; Wang T; Liu Z; Tang S; Huang H; Wu L; Sun Y
Integr Cancer Ther; 2024; 23():15347354241233258. PubMed ID: 38369762
[TBL] [Abstract][Full Text] [Related]
10. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
11. Anti-apoptotic effect of heat shock protein 90 on hypoxia-mediated cardiomyocyte damage is mediated via the phosphatidylinositol 3-kinase/AKT pathway.
Wang W; Peng Y; Wang Y; Zhao X; Yuan Z
Clin Exp Pharmacol Physiol; 2009 Sep; 36(9):899-903. PubMed ID: 19298537
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT/GSK-3β/β-catenin signaling.
Liang GH; Liu N; He MT; Yang J; Liang ZJ; Gao XJ; Rahhal AH; He QY; Zhang HT; Zha ZG
J Cell Biochem; 2018 Jan; 119(1):948-959. PubMed ID: 28681940
[TBL] [Abstract][Full Text] [Related]
14. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
Saturno G; Valenti M; De Haven Brandon A; Thomas GV; Eccles S; Clarke PA; Workman P
Oncotarget; 2013 Aug; 4(8):1185-98. PubMed ID: 23852390
[TBL] [Abstract][Full Text] [Related]
15. siRNA Targeting of the SNCG Gene Inhibits the Growth of Gastric Carcinoma SGC7901 Cells in vitro and in vivo by Downregulating the Phosphorylation of AKT/ERK.
Fan C; Liu J; Tian J; Zhang Y; Yan M; Zhu C
Cytogenet Genome Res; 2018; 154(4):209-216. PubMed ID: 29902801
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
17. Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis.
Redlak MJ; Miller TA
Dig Dis Sci; 2011 Feb; 56(2):323-9. PubMed ID: 20585984
[TBL] [Abstract][Full Text] [Related]
18. Destabilization of akt promotes the death of myeloma cell lines.
Zhang Y; Fu Y; Zhang F; Liu J
Biomed Res Int; 2014; 2014():190629. PubMed ID: 25243120
[TBL] [Abstract][Full Text] [Related]
19. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
20. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
